John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, discusses how high-deductible health plans are affecting patients' access to prescription drugs, PhRMA's concerns about the 340B drug discount program and its legislative priorities in Congress this year. He spoke with Modern Healthcare reporter Jaimy Lee.
See an excerpted version of this interview: Troubled by health plans' high cost-sharing for drugs
